The Latest in Multiple Sclerosis

Neurology Reviews

Transitioning From Nonpegylated to Pegylated Interferon Beta-1a

June 7, 2016

Multiple Sclerosis

Clinical Neurology News

MS imaging guidelines from North American group offer standardized protocols

June 5, 2016

Multiple Sclerosis

Neurology Reviews

Dimethyl Fumarate and Fingolimod May Decrease Relapse Rate More Than Other DMTs

June 2, 2016

Multiple Sclerosis

Neurology Reviews

Alemtuzumab-Associated Improvement Is Sustained for More Than Five Years

June 2, 2016

Multiple Sclerosis

Neurology Reviews

BENEFIT 11: An 11-Year Follow-Up of Early Treatment With Interferon Beta-1b

June 2, 2016

Multiple Sclerosis

Neurology Reviews

Online Survey Probes Patient and Physician Preferences for First-Line MS Treatment

June 2, 2016

Multiple Sclerosis

Neurology Reviews

MS Misdiagnosis in the Era of McDonald Criteria

June 1, 2016

Multiple Sclerosis

Clinical Neurology News

Zinbryta approved by FDA for relapsing forms of multiple sclerosis

June 1, 2016

Multiple Sclerosis

Neurology Reviews

Reanalysis of Cladribine Data Confirms and Extends the Benefits Seen in ORACLE-MS

May 26, 2016

Multiple Sclerosis

Neurology Reviews

Does Natalizumab Benefit Patients With Secondary Progressive MS?

May 26, 2016

Multiple Sclerosis

Clinical Neurology News

Age, lower baseline ALC increase dimethyl fumarate lymphopenia risk

May 26, 2016

Multiple Sclerosis

Clinical Neurology News

Ocrelizumab bests interferon for relapsing MS at 2 years

May 25, 2016

Multiple Sclerosis

Clinical Neurology News

Screen and treat MS patients for emotional distress, depression

May 17, 2016

Multiple Sclerosis

Clinical Neurology News

Data support safety of MS drugs before, during early pregnancy

May 15, 2016

Multiple Sclerosis

Neurology Reviews

Evidence Builds for Mesenchymal Stem Cell Therapy in Multiple Sclerosis

May 3, 2016

Multiple Sclerosis